A phase 1b/2 multiple-dose safety study and pharmacokinetic/pharmacodynamic study of LY2189102 in patients with rheumatoid arthritis

Trial Profile

A phase 1b/2 multiple-dose safety study and pharmacokinetic/pharmacodynamic study of LY2189102 in patients with rheumatoid arthritis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs LY 2189102 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2008 Checked against the ClinicalTrials.gov record.
    • 30 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top